Evicenter
Darzalex (daratumumab) in Multiple myeloma
Manufacturer
Janssen Biotech, Inc.
Questions
61
Last updated

All questions

Indication: Darzalex (daratumumab) in multiple myeloma

5 questions · 3 sources

Indication

What is Darzalex Faspro approved for in multiple myeloma?

“DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14)]: • multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. • multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. • multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. • multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. • multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. • multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. • multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. • multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. • multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma.” (opens the source at this quote in a new tab)

Note: The label also lists newly diagnosed light chain (AL) amyloidosis, in combination with bortezomib, cyclophosphamide, and dexamethasone.

What is Darzalex (daratumumab) IV approved for?

Which Darzalex regimens are approved for newly diagnosed multiple myeloma?

Applies to Newly diagnosed multiple myeloma, transplant-eligible and transplant-ineligible

Is Darzalex Faspro approved for maintenance therapy after transplant?

Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

Drug names

What is the generic name for Darzalex and Darzalex Faspro?

Note: Both passages are the title lines of the Prescribing Information: the first for DARZALEX, the second for DARZALEX FASPRO.